Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Research & Development (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Research & Development data on record, last reported at $16.6 million in Q4 2025.

  • For Q4 2025, Research & Development rose 83.74% year-over-year to $16.6 million; the TTM value through Dec 2025 reached $52.6 million, up 56.75%, while the annual FY2025 figure was $52.6 million, 56.75% up from the prior year.
  • Research & Development reached $16.6 million in Q4 2025 per ACRS's latest filing, up from $13.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $26.6 million in Q4 2023 and bottomed at $6.0 million in Q3 2024.
  • Average Research & Development over 5 years is $15.3 million, with a median of $14.0 million recorded in 2021.
  • Peak YoY movement for Research & Development: soared 137.8% in 2022, then crashed 75.05% in 2024.
  • A 5-year view of Research & Development shows it stood at $14.1 million in 2021, then soared by 49.43% to $21.1 million in 2022, then grew by 26.45% to $26.6 million in 2023, then tumbled by 66.13% to $9.0 million in 2024, then soared by 83.74% to $16.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $16.6 million in Q4 2025, $13.0 million in Q3 2025, and $11.4 million in Q2 2025.